FilingsTodayHome › Companies › Dong-A Pharmaceutical
Dong-A Pharmaceutical
동아제약 · 000640 · KOSPI
Filings, last 12 months
143
Supply contracts
8
Insider reports
30
Share & bond issues
0
At a glance
Dong-A Pharmaceutical filed 143 disclosures in the last 12 months, including 30 insider, 8 contract, 7 5% holder, 4 earnings, 4 buyback and 1 m&a. The most recent key filing was on Oct 27: Operating profit ₩35.1B, up 5.4% YoY. Revenue ₩431B, up 12.7% YoY.
Revenue for 2025 was ₩1.43T, up 7.2% on 2024. Operating margin was 6.8% against 6.2% a year earlier. Debt was 81% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩763B and operating profit of ₩58.1B.
New contracts, last 12 months
3 new supply contracts worth 114% of the revenue stated in the filings.
Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.
Financial summary
2023
Revenue ₩1.13T
Op. profit ₩76.9B
Debt/equity 91%
2024
Revenue ₩1.33T
Op. profit ₩82.1B
Debt/equity 91%
2025
Revenue ₩1.43T
Op. profit ₩97.8B
Debt/equity 81%
2026 H1
Revenue ₩763B
Op. profit ₩58.1B
Debt/equity 83%
RevenueOperating profitOperating lossConsolidated where available · from periodic reports
Key filings
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/8InsiderInsider ownership report
10/25% holderReport of 5%+ holding
9/2InsiderInsider ownership report
9/25% holderReport of 5%+ holding
8/275% holderReport of 5%+ holding
7/27EarningsPreliminary operating results
7/27M&AAmendedMerger
7/23M&AMerger
7/10ContractAmendedSingle sales/supply contract
7/7InsiderInsider ownership report
7/2InsiderInsider ownership report
4/27EarningsPreliminary operating results
4/20ContractSingle sales/supply contract
4/2InsiderInsider ownership report
3/31InsiderInsider ownership report
3/31InsiderInsider ownership report
3/31InsiderInsider ownership report
3/31InsiderInsider ownership report
3/31InsiderInsider ownership report
3/31InsiderInsider ownership report
3/31InsiderInsider ownership report
3/31InsiderInsider ownership report
3/31InsiderInsider ownership report
3/31InsiderInsider ownership report
3/315% holderReport of 5%+ holding
3/16ContractSingle sales/supply contract
3/16ContractSingle sales/supply contract
3/16InsiderInsider ownership report
3/10ContractSingle sales/supply contract
2/23BuybackShare cancellation
2/12BuybackTreasury stock disposal
2/9EarningsPreliminary operating results
1/23ContractSingle sales/supply contract
1/16BuybackTreasury stock disposal
1/16BuybackTreasury stock disposal
1/95% holderReport of 5%+ holding
1/5InsiderInsider ownership report
12/22ContractAmendedSingle sales/supply contract
12/11IssuanceAmendedConvertible bond issue
12/4ContractAmendedSingle sales/supply contract
11/7InsiderInsider ownership report
11/7InsiderInsider ownership report
11/75% holderReport of 5%+ holding
11/75% holderReport of 5%+ holding
Other filings
10/30Filing
10/27IR event
10/22IR event
10/22Filing
10/8Filing
10/2Filing
10/2Filing
10/2Merger
9/7Filing
9/4Filing
9/2Filing
8/14Half-year report
8/13Filing
8/13Filing
8/13Filing
7/27IR event
7/23Filing
7/23IR event
7/23Filing
7/20Filing
7/16Dividend
7/16Dividend
6/18Filing
6/18Filing
5/29Filing
5/15Quarterly report
4/27IR event
4/23Filing
4/23IR event
4/23Filing
4/21Dividend
4/16Filing
3/31Filing
3/26Filing
3/18Audit report
Links open the original filing on DART, in Korean.